China's Medical Service Pricing Reform: Impact on Innovative Medical Technology Pricing and Adoption

Presented by: NRDL+ Executive Debrief

Launch Date: 10/28/24

Stay ahead of value-based approval and pricing trends for medical services and discover strategic growth opportunities to support clinical and commercial strategies for innovative medical technologies in China.

MedTech companies are accelerating innovation in China, where public hospitals play a pivotal role. These hospitals employ 64% of licensed doctors, manage 82% of inpatient admissions, and handle 40% of ambulatory visits, accounting for nearly half of the country's total health expenditure.

This central role also contributes to China's unique approach to regulating medical service prices. Unlike many developed markets, public hospitals in China must adhere to the provincial medical service price catalog in order to offer and bill for treatments. While private hospitals have more flexibility to set their own prices, they often align with these standards to qualify as BMI-designated institutions and remain competitive.

For new technologies that fill clinical gaps, simplify complex procedures, or offer innovative treatments, securing a spot in a provincial medical service price catalog with optimized pricing is critical for success in China’s inpatient and outpatient markets.

In this course, you'll learn how China's medical service pricing reform affects the pricing and commercialization of innovative medical technologies. You’ll stay ahead of value-based approval and pricing trends, uncover strategic growth opportunities, and access practical planning guides and provincial policy summaries. These resources will help you strengthen your policy monitoring and implementation and support your clinical and commercial strategy development.

Who is this course for?

• Global life sciences commercial and market access leaders aiming to enhance pricing and access strategies in China
• Policy leaders working to create a supportive environment for innovative medicines in China
• Product development executives planning strategies for innovative portfolios in China and globally
• Business development and investment professionals seeking to maximize partnerships and investments in China

Upon completing this course, you will:

This course includes:

• 45-minute video lessons
• Exercises to apply learning
• Practical planning guides
• Provincial policy summaries in both English and Chinese
• Annual updates to course materials and policy summaries
• 50% discount on renewals

Course Syllabus:

Section One: Medical Service Pricing Governance and Management in China

1. Governance and Management: Key Agencies, Roles, and Responsibilities
2. The Connection Between Medical Service Pricing and Medical Device Pricing

Section Two: Key Focus Areas in China’s Medical Service Pricing Reform – Effects on Innovative Medical Technology Pricing and Adoption

1. Regional Disparities
   (1) Issues
   (2) Solutions
   (3) Implications for Manufacturers

Download: Planning Guide 1

2. Properly Reflecting Human Care
   (1) Issues
   (2) Solutions
   (3) Implications for Manufacturers

Download: Planning Guide 2

3. Supporting Medical Innovation
   (1) Issues
   (2) Solutions

Section Three: Provincial Trends in Value-Based Approval and Pricing for New Medical Services in China: MedTech’s Strategy

1. Overview of the New Medical Service Price Item Setup Process
2. Key Developments
3. Implications for Manufacturers

Download: Planning Guide 3
Download: Specific Requirements for Innovation and Economic Evaluations Across Key Provinces in China (Chinese and English Versions)

About the Course Creator: Kelly Ke

• An award-winning management consultant at Deloitte
• Founder bizi, an access agency aiding life sciences firms with pricing, reimbursement, and access challenges in the US and globally for more than a decade, and
• The author of the NRDL+, a newsletter examining China's access policies and pathways for innovative medical technologies, boasting a membership that includes leaders from top-tier life sciences companies, prominent university researchers, and expert consultants.

Frequently Asked Questions